StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.0
  1. Startseite
  2. /Verbindung

Estramustin

Estramustine

HCID 259331
Neue NotizNeue ReaktionAnfrage stellen
Druckvorschau

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
2998-57-4
Standard-SMILES
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
InChIKey
FRPJXPJMRWBBIH-RBRWEJTLSA-N
Summenformel
C23H31Cl2NO3
Durchschnittliche Molmasse
440,4 g/mol
Monoisotopische Masse
439,16809921

Überblick

Estramustine is a carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid. It has a role as an alkylating agent, an antineoplastic agent and a radiation protective agent. It is a carbamate ester, a 17beta-hydroxy steroid and an organochlorine compound. It is functionally related to a 17beta-estradiol.

Namen und Bezeichner

Bevorzugter Name
Estramustine
IUPAC
[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate
Lokaler Name
Estramustin
Englischer Name
Estramustine
Summenformel
C23H31Cl2NO3
Molmasse
440.4

Namen und Synonyme

estramustine2998-57-4EstramustinumEstramustinaLeo-275DTXSID8046458LEO 275Leo275NSC-89201Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)17beta-Estradiol 3-(bis(2-chloroethyl)carbamate)Estradiol 3-[bis(2-chloroethyl)carbamate]
Weitere Namen anzeigen
AlestramustineEstractyNSC89201NSC 89201EstamustineEstramustinEstramustine USP/EP/BP
RO 21-8837Ro 22-2296/000Ro-22-2296/000[(8R,9S,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] N,N-bis(2-chloroethyl)carbamate35LT29625AEstradiol 3-(bis(2-chloroethyl)carbamate)Ro-222296000CHEBI:4868

Datenbank-Bezeichner

CAS
2998-57-4
PubChem CID
259331
DTXSID

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
4
Polarare Oberfläche (TPSA)
49,8 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
3
Frei drehbare Bindungen
6
Schwere Atome
29
Formalladung
0
Komplexität
584

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LipidsLipids -> Sterol Lipids [ST] -> Steroids [ST02] -> C18 steroids (estrogens) and derivatives [ST0201]
LogP5.7
Solubility3.85e-04 g/L
Endocrine DisruptorsPotential endocrine disrupting compound
Melting Point104.5 °C
Physical DescriptionSolid

Physikochemische Eigenschaften

Schmelzpunkt
104 · 104-105°
Siedepunkt
565.8 · 565.8±50.0 °C(Predicted)
Dichte
1.253 · 1.253±0.06 g/cm3(Predicted)
storage temp.

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 5 Einträge

This chemical does not meet GHS hazard criteria for 3% (1 of 33) of reports.

Danger

H351 (93.9%): Suspected of causing cancer [Warning Carcinogenicity]

P203, P280, P318, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 33 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesCarc. 2 (93.9%)

Toxikologische Informationen

Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

estramustine

DILI Positive

Oral

DOI:10.1016/j.drudis.2019.09.022

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

L01XX11

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Pharmacodynamics · 1 Eintrag

Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard moiety becomes active and participates in alkylation of DNA or other cellular components.. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage.

Mechanism of Action · 1 Eintrag

Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors.

Biological Half-Life20 hours
FDA Pharmacological Classification · 6 Einträge

35LT29625A

ESTRAMUSTINE

Mechanisms of Action [MoA] - Alkylating Activity

Established Pharmacologic Class [EPC] - Alkylating Drug

Chemical Structure [CS] - Estradiol

Chemical Structure [CS] - Nitrogen Mustard Compounds

MeSH Pharmacological Classification · 2 Einträge

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Zugehörige Reaktionen

1
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 22633
HRID 22633als Eduktuspto-grants-2005_02

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Weitere Aktionen
Neue NotizNeue ReaktionAnfrage stellen
DTXSID8046458
ChEMBL
CHEMBL1575
ChEBI
CHEBI:4868
UNII
35LT29625A
EC Number
221-076-3
Nikkaji
J7.659G
-20 °C · Store at -20°C
Aggregatzustand
Solid
pka
15.05 · 15.05±0.40(Predicted)
Farbe
White to off-white
Wasserlöslichkeit
1 mg/L · 1mg/L(30 ºC)
InChIKey
FRPJXPJMRWBBIH-SZZXFXARNA-N
SMILES
[C@@]12([H])CCC3C=C(OC(=O)N(CCCl)CCCl)C=CC=3[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])O |&1:0,20,24,26,29,r|
CAS Datenbank
2998 · 2998-57-4(CAS DataBase Reference)

Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)

Absorption, Distribution and ExcretionThe metabolic urinary patterns of the estradiol moiety of estramustine phosphate and estradiol itself are very similar, although the metabolites derived from estramustine phosphate are excreted at a slower rate.
Cellular LocationsCytoplasm

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >250

Anwendungen

VerwendenAntineoplastic.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Leo 271 fBis(2-chlorethyl)carbamoylchloridEstradiol

Ergänzende Hinweise

DefinitionChEBI: A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.